Frontiers in Immunology (Oct 2024)

Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice

  • Gangyuan Ma,
  • Gangyuan Ma,
  • Zeping Xu,
  • Chinyu Li,
  • Feng Zhou,
  • Bobo Hu,
  • Junwei Guo,
  • Changwen Ke,
  • Liqing Chen,
  • Guilin Zhang,
  • Hungyan Lau,
  • Hudan Pan,
  • Hudan Pan,
  • Xixin Chen,
  • Runze Li,
  • Runze Li,
  • Liang Liu,
  • Liang Liu,
  • Liang Liu

DOI
https://doi.org/10.3389/fimmu.2024.1451433
Journal volume & issue
Vol. 15

Abstract

Read online

IntroductionRespiratory Syncytial Virus (RSV) is a significant cause of respiratory illnesses worldwide, particularly in infants and elderly individuals. Despite the burden RSV imposes, effective preventive measures are limited. The research application of adeno-associated virus (AAV) in vaccine platforms has been expanding, and its potential in prevention and treatment has garnered much attention.MethodsIn this study, we explored the potential application of a recombinant adeno-associated virus 5 (rAAV5) vector-based RSV vaccine, focusing on the expression of the pre-fusion (Pre-F) protein structure. Through intramuscular immunization in mice. The immunogenicity of the vaccine was evaluated in Balb/c mice immunized intramuscularly and intranasal, respectively.ResultsThe rAAV5-RSV-Fm vaccine demonstrated positive humoral and induced antibody titers against RSV strains A and B for up to 120 days post-immunization. Notably, intranasal administration also elicited protective antibodies. Characterization studies confirmed the ability of the vac-cine to express the Pre-F protein and its superior immunogenicity compared to that of full-length F protein.ConclusionThese findings underscore the potential application of rAAV5 vector platforms in RSV vaccine development and further investigation into their protective efficacy is warranted.

Keywords